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Abstract
Background—The effectiveness of psoriasis therapies in real-world settings remains relatively 
unknown.
Objective—To compare the effectiveness of less commonly used systemic monotherapies and 
commonly used combination therapies for psoriasis.
Methods—Multi-center cross-sectional study of 203 patients with plaque psoriasis receiving less 
common systemic monotherapy (acitretin, cyclosporine, or infliximab) or common combination 
therapies (adalimumab, etanercept, or infliximab and methotrexate) compared to 168 patients 
receiving methotrexate evaluated at one of ten US outpatient dermatology sites participating in the 
Dermatology Clinical Effectiveness Research Network.
Results—In adjusted analyses, patients on acitretin (relative response rate 2.01; 95% confidence 
interval, 1.18–3.41), infliximab (1.93; 1.26–2.98), adalimumab and methotrexate (3.04; 2.12–
4.36), etanercept and methotrexate (2.22; 1.25–3.94), and infliximab and methotrexate (1.72; 
1.10–2.70) were more likely to have clear or almost clear skin compared to patients on 
methotrexate. There were no differences among treatments when response rate was defined by 
health-related quality of life.
Limitations—Single time point assessment may result in overestimation of effectiveness.
Conclusions—The efficacy of therapies in clinical trials may overestimate their effectiveness as 
utilized in clinical practice. While physician-reported relative response rates were different among 
therapies, absolute differences were small and did not correspond to differences in patient-reported 
outcomes.
Keywords
Psoriasis; Systemic treatments; Biologics; Comparative effectiveness; Combination therapy; 
Physician Global Assessment; Quality of life; Dermatology Life Quality Index
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Introduction
Psoriasis is a common chronic inflammatory disease that affects approximately 125 million 
people worldwide.1 Nearly 25% with psoriasis have moderate-to-severe disease1 which is an 
indication for treatment with systemic therapy or phototherapy. Despite the major advances 
in psoriasis treatments that have accompanied the development of several targeted biologic 
medications over the past decade, there are few head-to-head comparisons of the currently 
available psoriasis therapies. As a result, no clear first line therapy for moderate-to-severe 
psoriasis exists.2 Additionally, while clinical trials generally report high efficacy, especially 
for biologic therapies, clinical experience and long-term follow-up of patients receiving 
biologics suggest loss of efficacy over time.3,4 Furthermore, we have observed that the 
efficacy of treatments as reported in clinical trials may overestimate their effectiveness as 
utilized in the clinical setting.5 Additional comparative effectiveness studies of moderate-to-
severe psoriasis therapies are, therefore, greatly needed to help guide physicians’ and 
patients’ treatment choices in the real-world setting. The purpose of this multicenter cross-
sectional study was to expand our previous comparative effectiveness study findings by 
determining the effectiveness of less commonly used systemic monotherapies and 
commonly used combination therapies for treatment of moderate-to-severe psoriasis.
Methods
Study Design and Participant Protection
We conducted a multicenter cross-sectional study to determine the effectiveness of less 
commonly used systemic monotherapy and commonly used combination therapies for 
moderate-to-severe psoriasis. The study was approved by the University of Pennsylvania 
and University of Utah institutional review boards, and informed consent was obtained from 
all patients. The study was conducted in accordance with the Declaration of Helsinki and 
reported in accordance with the Strengthening the Reporting of Observational Studies in 
Epidemiology guidelines.6
Setting
Data were collected by 12 clinicians (10 dermatologists and 2 physician assistants) who are 
members of the Dermatology Clinical Effectiveness Research Network (DCERN). DCERN 
includes 2 academic medical centers (University of Pennsylvania and University of Utah, 
each with a hospital-based site and a separate community-based site) and 6 private practices 
in Georgia, Pennsylvania, New York, and Colorado (see www.dermcern.org for details). 
Patient data were collected prospectively at a single, regularly scheduled clinic appointment 
from February 2010 through June 2011.
Participants
As previously described in detail, broad inclusion criteria were used to enroll consecutive 
patients seen by their dermatology provider in DCERN practices for a routine follow-up 
appointment in order to minimize selection bias.5 Eligible participants included patients who 
met at least one of the following criteria: were currently receiving or had previously 
received systemic therapy or phototherapy prescribed by a dermatology provider for 
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treatment of psoriasis; or were candidates for systemic therapy with a documented history of 
at least 5% body surface area (BSA) involvement. In the analyses presented, we included 
patients who were currently receiving a single less commonly used oral systemic or biologic 
therapy (acitretin, cyclosporine, or infliximab) or a commonly used combination of therapies 
(methotrexate and either adalimumab, etanercept, or infliximab) for a primary indication of 
plaque psoriasis.
Variables
As previously described, detailed patient and provider level data were collected by trained 
study coordinators using standardized case report forms and via patient self-report with 
confirmation by the patient’s dermatology clinic record and assessments by the clinician 
investigators.5 The main exposures were current less common monotherapy or common 
combination therapy, and the other variables served as potential confounders or effect 
modifiers. The primary outcome was a widely used 6-point Physician Global Assessment 
(PGA) scale of psoriasis lesions (0, clear; 1, minimal; 2, mild; 3, moderate; 4, marked; and 
5, severe; scored separately for erythema, induration, and scaling and then averaged), 
dichotomized as clear or almost clear disease (0–1) vs. mild to severe disease (2–5).7,8 
Secondary outcomes were also evaluated including the Psoriasis Area and Severity Index 
(PASI) and affected BSA as objective outcomes, and the Dermatology Life Quality Index 
(DLQI) and patient report of prescription topical medication use within the past week as 
patient-reported outcomes. The PASI was dichotomized such that a score of 2 or less was 
considered to indicate no or minimal disease (based on a receiver operating characteristic 
analysis comparing PASI scores with PGA scores). Presence of psoriasis involving less than 
3% BSA was considered to be mild disease based on National Psoriasis Foundation 
definitions, which have been extensively used in research.9 Previously published banding of 
DLQI scores was used to determine cutoff points upon which to dichotomize DLQI as an 
outcome.10
Study Size
Target enrollment was established for the primary comparative effectiveness study,5 within 
which the current study was nested. This study was descriptive in nature, thus the sample 
size was not determined a priori. The maximum number of eligible subjects was included, 
and all effect measures are reported with 95% confidence intervals (CIs).
Statistical Analysis
First, the patient population was characterized using descriptive statistics. Univariate 
analyses were conducted using the one-way analysis of variance (ANOVA) or Kruskal-
Wallis tests for grouped continuous data; and χ2 or Fisher’s exact test for dichotomous or 
categorical data. Multivariable analyses were performed using modified Poisson regression 
with robust error variance to determine which factors independently predicted optimal 
patient outcomes as defined in the “Variables” section.11 Methotrexate was chosen as the 
reference treatment since it is often considered the standard against which novel therapies 
are compared. To build our multivariable model, we used a purposeful selection approach in 
which all covariates thought to be clinically relevant a priori and any covariates with a 
significance at P<0.10 in univariate analyses were included in the initial model.12 
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Nonsignificant covariates were eliminated from the model if their removal did not change 
the risk ratio estimates of other covariates by more than 10%. Variables were considered for 
removal first if they were included in the model base on P value and subsequently based on 
their perceived clinical importance. Model fit was assessed using goodness-of-fit tests based 
on deviance and Pearson statistics. The modified Poisson modeling approach was used to 
yield the clinically relevant statistic of relative response rate (i.e., relative risk) which was 
then used to calculate the relative response difference and the number needed to treat. As a 
sensitivity analysis, we performed logistic regression and converted odds ratios to relative 
risks using published formulas.13 We also performed additional sensitivity analyses 
including varying the outcome definition by using PASI, BSA, and DLQI and restricting the 
analysis to patients on at least 3 months of therapy. Missing data did not exceed 2.7% for 
any of the variables analyzed, and patients with missing data were excluded from analyses.
Results
The baseline characteristics of 371 patients receiving methotrexate (reference therapy), less 
common systemic monotherapies, or common combination therapies for the primary 
indication of plaque psoriasis are summarized in Table 1. In addition to having plaque 
psoriasis, 75 (20.2%) patients also had other types of psoriasis as follows: 38 (10.2%) with 
scalp, 20 (5.4%) with guttate, 22 (5.9%) with nail, 16 (4.3%) with inverse or genital, 11 
(3.0%) with palmar plantar, and 2 (0.5%) with pustular psoriasis (data not shown). Mean 
age, practice setting of the patient’s dermatologist, median body mass index (BMI), median 
psoriasis duration, psoriasis extent at its worst, and prevalence of physician-diagnosed 
psoriatic arthritis were each found to be significantly different among the therapies 
examined. Treatment characteristics are summarized in Table 2. Patients receiving 
infliximab monotherapy (24 months; interquartile range [IQR], 7–60) and infliximab and 
methotrexate combination therapy (18 months; IQR, 6–44) exhibited the longest median 
uninterrupted treatment duration compared to the other examined therapies (p = 0.003), 
Notably, a high proportion of patients on infliximab alone (70.7%) or in combination with 
methotrexate (79.4%) were receiving doses greater than 5 mg/kg every 8 weeks. A 
comparison of the median methotrexate doses for patients on methotrexate alone (15 mg/
week; IQR, 15–20) and in combination with adalimumab (10 mg/week; IQR, 7.5–15), 
etanercept (11.3 mg/week; IQR, 7.5–17.5), or infliximab (15 mg/week; IQR 10–22.5) 
demonstrated methotrexate doses to be lower among patients receiving adalimumab or 
etanercept and methotrexate combination therapies (p < 0.001). The median number of prior 
therapies used was also significantly different among the treatment groups (p < 0.001) with 
patients on infliximab and methotrexate combination therapy (3; IQR, 1–4) and infliximab 
monotherapy (2.5; IQR 1–5) reporting the greatest number of previous treatments.
Across all examined treatment groups, there were significant differences in median PGA (p 
= 0.001), PASI (p < 0.001), and BSA (p < 0.001), though absolute differences were small 
(Table 3). There was no significant difference in median DLQI (p = 0.08). Frequency of 
prescription topical medication use during the preceding week was significantly different 
among treatment groups with patients on acitretin reporting the most frequent use (p < 
0.001) (Table 2). Crude response rate defined by PGA ≤ 1, which corresponds to being clear 
or almost clear of psoriasis, was highest for adalimumab and methotrexate combination 
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therapy (59.2%; 95% CI, 44.2%–73.0%) and lowest for methotrexate monotherapy (22.3%; 
95% CI 16.2%–29.3%) (Table 3). In contrast, when the outcome was defined by DLQI ≤ 5, 
which corresponds to no or small effect on the patient’s quality of life, crude response rates 
were generally higher but not significantly different among therapies (p = 0.43).
Patients who were clear or almost clear of psoriasis (PGA ≤ 1) were more likely to be 
underweight or normal weight and treated in a private practice setting, and they were less 
likely to have used prescription topical medications in the preceding week (data not shown). 
Compared to methotrexate, adjusted relative rates of PGA response were significantly 
higher for all treatment groups except cyclosporine which was associated with a higher but 
not statistically significant relative response rate (Table 4). For the therapies with 
statistically significant response rate differences, the number needed to treat (NNT) ranged 
from 2.2 for adalimumab and methotrexate combination therapy to 6.2 for infliximab and 
methotrexate combination therapy. The significance of the NNT is that, for example, 3 
patients (rounded up from 2.2 per convention) would need to be treated with adalimumab 
and methotrexate combination therapy in order for 1 additional patient to reach treatment 
response over what would be expected from methotrexate monotherapy of the same 3 
patients.
In sensitivity analyses, we found no differences in response rates when DLQI was defined as 
the outcome (data not shown). When the outcome was defined by BSA or PASI, the 
differences in response rates were attenuated for all therapies, and statistical significance 
was lost in the cases of infliximab and acitretin monotherapy, respectively. In order to 
ensure capture of maximal effect on current therapy, we restricted our analyses to those 
patients on at least 3 months of therapy and found crude response rates to be similar to those 
of the primary analysis (data not shown).
Discussion
In this comparative effectiveness study of less commonly used systemic monotherapies and 
common combination therapies for moderate-to-severe psoriasis in the real-world clinical 
setting, we report similar findings to those of our previous study of the effectiveness of 
common systemic monotherapies and phototherapy.5 Using a single PGA assessment, the 
proportions of patients achieving clear or almost clear response to treatment were 50% or 
less for all examined therapies except for adalimumab and methotrexate combination 
therapy (59.2%). Importantly, the effectiveness of therapies was lower than their efficacy as 
reported in randomized controlled trials (RCTs). For example, the proportion of patients 
with clear or almost clear skin on infliximab in our study compared to the European 
Infliximab for Psoriasis (Remicade) Efficacy and Safety Study I (EXPRESS I)14 (an RCT of 
infliximab vs. placebo) was 46.3% vs. 74% (Table 2). Similarly, the PGA response rate for 
patients on etanercept and methotrexate combination therapy in our study compared to an 
RCT of etanercept and methotrexate vs. etanercept only15 was 50.0% vs. 71.8%.
More than 70% of patients on either infliximab monotherapy or infliximab and methotrexate 
combination therapy were receiving higher doses than what is approved by the FDA (i.e., 
>5mg/kg every 8 weeks). The proportions of patients receiving escalated doses of infliximab 
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were higher than what we observed with adalimumab or etanercept alone (11.8% and 
36.1%, respectively)5 or in combination with methotrexate (18.4% and 22.8%, respectively). 
Additionally, median duration of uninterrupted therapy was longest for infliximab 
monotherapy compared to all other available monotherapies5 and common combination 
therapies, suggesting greater treatment persistence with infliximab. This finding is consistent 
with a Danish study that similarly reported infliximab to have the highest drug survival rate 
compared to adalimumab and etanercept.3 In contrast, RCT data suggest infliximab to have 
lower patient retention rates compared to other biologic therapies.16 The greater treatment 
persistence that we and Gniadecki et al.3 observed may be explained by infliximab being the 
only FDA approved tumor necrosis factor-a inhibitor to have weight-based dosing, and by 
use of off-label dosing schedules in the clinical setting, as noted in our study. In contrast, 
median duration of uninterrupted therapy was shortest for cyclosporine which is expected 
considering the known renal and other potential toxicities associated with long-term use.
In multivariable analyses, we found all examined therapies except for cyclosporine to be 
significantly more effective than methotrexate based on PGA response, even after 
adjustment for multiple potential confounding variables. The relatively low and statistically 
nonsignificant relative response rate associated with cyclosporine is consistent with RCTs 
that have shown mixed results of both equal and greater efficacy compared to 
methotrexate.17,18 Furthermore, almost half of the patients on cyclosporine were receiving 
low doses (<2.5 mg/kg/d) which may, in part, account for its low effectiveness observed in 
our study. Though the relative response rates of most of the therapies examined were 
significantly higher than that of methotrexate, the absolute differences in PGA response 
among therapies were small. Additionally, our sensitivity analyses revealed relative 
response rates to be dependent on the outcome definition. When DLQI was used as a 
patient-reported outcome, we generally observed greater crude response to therapy 
compared to physician-reported outcomes. However, in adjusted analyses, the relative 
response rates were essentially equal across all evaluated therapies. Furthermore, differences 
in PGA response rates were not reflected in patient-reported use of prescription topical 
medication use. Thus, these patient-reported data suggest that observed differences in 
physician-reported response rates among therapies may not be clinically significant.
Our findings should be interpreted in light of the study’s strengths and limitations. Strengths 
include its broad inclusion criteria, high (95%) participation rate, patient population drawn 
from multiple clinical practices across the United States, and use of multivariable statistical 
models to account for potential confounding factors. Limitations include the cross-sectional 
design with assessment at a single time point which renders the study susceptible to the 
phenomenon of clinical drift and resulting possible overestimation of the effectiveness of 
therapies due to the fact that only those patients with good response to treatment continue on 
therapy. Additionally, the cross-sectional nature of our study prevents adequate assessments 
of time to treatment response, response duration, therapy compliance, and other factors that 
are important in determining treatment effectiveness. Treatment was also assigned in a non-
random manner which may result in residual confounding and channeling bias which are 
methodologically challenging to adjust for in the setting of our small study of less 
commonly used therapies for moderate-to-severe psoriasis. Finally, though the use of DLQI 
in clinical trials of biologic therapy for psoriasis suggests that it is highly correlated with 
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physician-reported outcomes such as PASI,19 it is possible that DLQI is not sensitive 
enough to detect differences in response to therapies used in the clinical setting.
In summary, our comparative effectiveness study of less commonly used systemic therapies 
and common combination therapies for treatment of moderate-to-severe psoriasis provides 
additional evidence to suggest that the performance of therapies for psoriasis in the real-
world clinical setting is lower than what is reported by RCTs for reasons that remain 
incompletely understood. We also confirmed our previous findings that absolute differences 
in objective response among therapies are small and may not translate to clinically 
significant differences. Importantly, we found infliximab to be associated with the longest 
duration of uninterrupted therapy among all therapies and that treatment persistence may be 
improved by biologic dose escalation. Together, our results further highlight the need for 
future longitudinal comparative effectiveness studies to better understand the performance 
of psoriasis therapies in the real world clinical setting.
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Capsule Summary
1. Little is known about the effectiveness of therapies for psoriasis in the real-
world setting.
2. Clinical trials may overestimate the effectiveness in the clinical setting. 
Objective response rates vary by treatment but patient-reported outcomes are 
similar in clinical practice.
3. Longitudinal comparative effectiveness studies of psoriasis therapies are 
needed.
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Table 4
Relative Response Rate of Physician Global Assessment Clearance,a and Response Rate Differences by 
Current Monotherapy and Combination Therapy
Current Treatment Unadjusted RR(95% CI)
Adjusted RR
(95% CI)b
Risk Difference
(95% CI)c NNT
d
Methotrexate sodium (n=168) 1 [Reference] 1 [Reference]
Acitretin (n=37) 1.58 (0.93–2.66) 2.01 (1.18–3.41) 0.22 (0.04–0.54) 4.4
Cyclosporine (n=19) 1.65 (0.86–3.18) 1.44 (0.75–2.74) 0.10 (−0.05–0.39) NA
Infliximab (n=42) 2.08 (1.35–3.21) 1.93 (1.26–2.98) 0.21 (0.06–0.44) 4.8
Adalimumab + Methotrexate (n=49) 2.66 (1.84–3.83) 3.04 (2.12–4.36) 0.45 (0.25–0.75) 2.2
Etanercept + Methotrexate (n=22) 2.24 (1.35–3.72) 2.22 (1.25–3.94) 0.27 (0.05–0.66) 3.7
Infliximab + Methotrexate (n=34) 1.98 (1.23–3.18) 1.72 (1.10–2.70) 0.16 (0.02–0.38) 6.2
Abbreviations: CI, confidence interval; NA, not applicable; NNT, number needed to treat; RR, relative risk.
a
Physician Global Assessment Clearance defined as clear or almost clear disease (PGA ≤ 1).
bAdjusted for age, sex, marital status, practice setting of dermatologist, body mass index, psoriasis response to natural light,prescription topical 
medication frequency.
c
Difference between adjusted and baseline risk.
dNumber of patients needed to treat with the particular treatment to gain 1 additional patient with PGA clearance relative to theresponse achieved 
with methotrexate.
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